AZT Stock Overview
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ArcticZymes Technologies ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr26.15 |
| 52 Week High | kr47.50 |
| 52 Week Low | kr24.20 |
| Beta | 0.94 |
| 1 Month Change | -4.21% |
| 3 Month Change | -33.88% |
| 1 Year Change | -30.54% |
| 3 Year Change | -72.75% |
| 5 Year Change | 513.85% |
| Change since IPO | 4.60% |
Recent News & Updates
ArcticZymes Technologies' (OB:AZT) Shareholders Have More To Worry About Than Only Soft Earnings
Feb 08
ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 04Recent updates
ArcticZymes Technologies' (OB:AZT) Shareholders Have More To Worry About Than Only Soft Earnings
Feb 08ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 04Investors Aren't Buying ArcticZymes Technologies ASA's (OB:AZT) Revenues
Feb 02ArcticZymes Technologies ASA's (OB:AZT) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Apr 29Downgrade: Here's How This Analyst Sees ArcticZymes Technologies ASA (OB:AZT) Performing In The Near Term
Apr 15One Analyst Just Shaved Their ArcticZymes Technologies ASA (OB:AZT) Forecasts Dramatically
Jan 13Here's What Analysts Are Forecasting For ArcticZymes Technologies ASA (OB:AZT) After Its First-Quarter Results
May 01What ArcticZymes Technologies ASA's (OB:AZT) P/E Is Not Telling You
Oct 28A Look At The Fair Value Of ArcticZymes Technologies ASA (OB:AZT)
Jul 26I Ran A Stock Scan For Earnings Growth And ArcticZymes Technologies (OB:AZT) Passed With Ease
Apr 28Can You Imagine How Elated ArcticZymes Technologies' (OB:AZT) Shareholders Feel About Its 992% Share Price Gain?
Mar 17Is Weakness In ArcticZymes Technologies ASA (OB:AZT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Jan 31
What Percentage Of ArcticZymes Technologies ASA (OB:AZT) Shares Do Insiders Own?
Jan 05Are ArcticZymes Technologies's (OB:AZT) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 01Shareholder Returns
| AZT | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -6.6% | -1.9% | -1.7% |
| 1Y | -30.5% | -77.0% | 1.8% |
Return vs Industry: AZT exceeded the Norwegian Biotechs industry which returned -77% over the past year.
Return vs Market: AZT underperformed the Norwegian Market which returned 1.8% over the past year.
Price Volatility
| AZT volatility | |
|---|---|
| AZT Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.9% |
Stable Share Price: AZT's share price has been volatile over the past 3 months.
Volatility Over Time: AZT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 60 | Michael Akoh | arcticzymes.com |
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally.
ArcticZymes Technologies ASA Fundamentals Summary
| AZT fundamental statistics | |
|---|---|
| Market cap | kr1.33b |
| Earnings (TTM) | kr18.72m |
| Revenue (TTM) | kr119.65m |
71.0x
P/E Ratio11.1x
P/S RatioIs AZT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZT income statement (TTM) | |
|---|---|
| Revenue | kr119.65m |
| Cost of Revenue | kr5.93m |
| Gross Profit | kr113.72m |
| Other Expenses | kr95.00m |
| Earnings | kr18.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.37 |
| Gross Margin | 95.05% |
| Net Profit Margin | 15.65% |
| Debt/Equity Ratio | 0% |
How did AZT perform over the long term?
See historical performance and comparison